| Original language | English (US) |
|---|---|
| Pages (from-to) | 2117-2119 |
| Number of pages | 3 |
| Journal | Movement Disorders |
| Volume | 39 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2024 |
Funding
This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute on Aging, NIH, Department of Health and Human Services; project number ZO1 AG000535 and ZIA AG000949, as well as the National Institute of Neurological Disorders and Stroke (NINDS) and the National Human Genome Research Institute. Data used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2; https://gp2.org ). GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research. Additional funding was provided by The Michael J. Fox Foundation for Parkinson's Research through grant MJFF\u2010009421/17483. The Accelerating Medicines Partnership Parkinson's Disease program is a public\u2010private partnership managed by the Foundation for the National Institutes of Health and funded by the NINDS in partnership with the ASAP initiative; Celgene Corporation, a subsidiary of Bristol\u2010Myers Squibb Company; GlaxoSmithKline plc; The Michael J. Fox Foundation for Parkinson's Research; Pfizer; Sanofi US Services; and Verily Life Sciences. The Global Parkinson's Genetics Program (GP2) from the author list should be also searchable in PubMed. Funding agencies:
ASJC Scopus subject areas
- Neurology
- Clinical Neurology